Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Tango Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
Novartis
National Cancer Institute (NCI)
Hutchmed
National Institutes of Health Clinical Center (CC)
Rigel Pharmaceuticals
Hoffmann-La Roche
National Cancer Institute (NCI)
Servier
Jonsson Comprehensive Cancer Center
Mayo Clinic
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited
Siriraj Hospital
NGM Biopharmaceuticals, Inc
University Health Network, Toronto
ABM Therapeutics Corporation
Novo Nordisk A/S
Hoffmann-La Roche
Quadriga Biosciences, Inc.
Celgene
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)